Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. reports news on its precision oncology business, including commercialization of KOMZIFTI™ (ziftomenib), an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Company updates also cover small-molecule drug candidates designed to target cancer signaling pathways across hematologic malignancies and solid tumors.
Recurring KURA developments include financial results, corporate updates, clinical data presentations, collaboration-related milestones, healthcare conference participation and Nasdaq inducement grants. News on darlifarnib (KO-2806) follows the company’s farnesyl transferase inhibitor program, including studies in combination with cabozantinib for clear cell renal cell carcinoma.
Kura Oncology (Nasdaq: KURA) reported first quarter 2026 results and launch metrics for AML drug KOMZIFTI (ziftomenib). Net product revenue reached $5.8 million with 85 new patient starts, 157 total prescriptions and >93% payer coverage across >12 million lives.
Total collaboration revenue was $12.5 million. Kura reported a net loss of $73.3 million, driven by higher R&D and SG&A expenses. Cash, cash equivalents and short-term investments totaled $580.8 million, and together with $180 million anticipated collaboration payments, are expected to fund the ziftomenib AML program through first KOMET-017 Phase 3 topline results, anticipated in 2028.
Kura Oncology (Nasdaq: KURA) and Kyowa Kirin will present updated frontline data from the Phase 1 KOMET-007 trial of ziftomenib + 7+3 in 99 newly diagnosed NPM1-m or KMT2A-r AML patients at the EHA 2026 Congress.
Reported results include CRc rates of 96% (NPM1-m) and 90% (KMT2A-r), MRD-negativity above 80%, and durable responses. A Phase 3 KOMET-017 trial is enrolling, and a virtual investor call is scheduled for June 3, 2026.
Kura Oncology (Nasdaq: KURA) will participate in the Bank of America Securities 2026 Healthcare Conference on May 13, 2026. Management is scheduled for a fireside chat at 6:00 p.m. ET / 3:00 p.m. PT. A live webcast and archived replay will be available on the company Investors website.
Kura Oncology (Nasdaq: KURA) will report first quarter 2026 financial results after market close on Tuesday, May 12, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a corporate update. A live webcast and archived replay will be available on the company Investors website.
Kura Oncology (Nasdaq: KURA) announced that on May 1, 2026 its Compensation Committee granted inducement nonstatutory stock options to five new employees to purchase 133,750 shares under the 2023 Inducement Option Plan, as amended.
Each option has an exercise price of $8.77 (closing price on May 1, 2026) and vests over four years (25% at one year, then monthly over 36 months), subject to continued service and applicable plan and agreement terms.
Kura Oncology (Nasdaq: KURA) reported preliminary subset data (N=16) showing the combination of darlifarnib plus cabozantinib produced a 44% objective response rate and 94% disease control rate in cabozantinib‑pretreated clear cell renal cell carcinoma (ccRCC) patients.
Tumor shrinkage occurred in 75% of patients, reductions ranged 32%–47% among responders, treatment durations reached 56 weeks, and six patients remained on therapy at data cut‑off. Safety was described as manageable across dose levels.
Kura Oncology (Nasdaq: KURA) will present updated Phase 1 FIT-001 data showing that darlifarnib combined with cabozantinib produced encouraging clinical activity and a manageable safety profile in advanced clear cell renal cell carcinoma patients previously treated with cabozantinib.
The presentation is scheduled for April 17, 2026 at IKCS Europe 2026; a virtual investor webcast and replay will follow at 7:30 a.m. PT / 10:30 a.m. ET.
Kura Oncology (Nasdaq: KURA) announced that on April 1, 2026 its Compensation Committee granted inducement nonstatutory stock options to six new employees totaling 153,750 shares under the 2023 Inducement Option Plan, as amended.
Each option has an $8.34 exercise price (April 1, 2026 closing price) and vests over four years: 25% at one year, then monthly over 36 months, subject to continued service and plan terms.
Kura Oncology (Nasdaq: KURA) announced that on March 2, 2026 the Compensation Committee granted inducement nonstatutory stock options to four new employees totaling 44,700 shares under the company’s 2023 Inducement Option Plan, as amended.
Each option has an exercise price of $8.68 (closing price on March 2, 2026) and vests over four years: 25% after one year and the remainder monthly over 36 months, subject to continued service and plan terms.
Kura Oncology (Nasdaq: KURA) reported Q4 and full-year 2025 results and a corporate update on March 5, 2026. Key highlights: KOMZIFTI FDA-approved for R/R NPM1-mutant AML, generated $2.1M in Q4 product revenue, and achieved Orange Book patent protection through July 2044. Company ended 2025 with $667.2M in cash and expects $180M in collaboration payments to fund KOMET-017 through topline Phase 3 results anticipated in 2028.
Pipeline advances include pivotal KOMET-017 frontline trials, FIT-001 Phase 1b expansion, and multiple 2026 clinical data milestones across AML and solid tumors.